Evidence map›Paper›PMID 33669287›Full record

ReviewInternational journal of molecular sciences2021

Preeclampsia: Cardiotonic Steroids, Fibrosis, Fli1 and Hint to Carcinogenesis.

Natalia I Agalakova, Nikolai I Kolodkin, C David Adair, Alexander P Trashkov, Alexei Y Bagrov

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Silencing ofJournal of the American Heart Association · 2023
    Article
  6. Fli1 and Tissue Fibrosis in Various Diseases.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Natalia I AgalakovaSechenov Institute of Evolutionary Physiology and Biochemistry, 44 Torez Prospect, 194223 St. Petersburg, Russia.
Nikolai I KolodkinState Institute of Highly Pure Biopreparations and Sechenov Institute of Evolutionary Physiology and Biochemistry, 44 Torez Prospect, 194223 St. Petersburg, Russia.
C David AdairDepartment of Obstetrics and Gynecology, University of Tennessee, Chattanooga, TN 37402, USA.ORCID 0000-0002-5422-227X
Alexander P TrashkovKonstantinov St. Petersburg Nuclear Physics Institute, National Research Centre Kurchatov Institute, 1 Orlova Roshcha, 188300 Gatchina, Russia.
Alexei Y BagrovSechenov Institute of Evolutionary Physiology and Biochemistry, 44 Torez Prospect, 194223 St. Petersburg, Russia.
Institute of Evolutionary Physiology and Biochemistry · RUKurchatov Institute · RUUniversity of Tennessee at Chattanooga · US

Funding

Russian Scientific Foundation 18-15-00222
6 · The paper itself

Abstract

Despite prophylaxis and attempts to select a therapy, the frequency of preeclampsia does not decrease and it still takes the leading position in the structure of maternal mortality and morbidity worldwide. In this review, we present a new theory of the etiology and pathogenesis of preeclampsia that is based on the interaction of Na/K-ATPase and its endogenous ligands including marinobufagenin. The signaling pathway of marinobufagenin involves an inhibition of transcriptional factor Fli1, a negative regulator of collagen synthesis, followed by the deposition of collagen in the vascular tissues and altered vascular functions. Moreover, in vitro and in vivo neutralization of marinobufagenin is associated with the restoration of Fli1. The inverse relationship between marinobufagenin and Fli1 opens new possibilities in the treatment of cancer; as Fli1 is a proto-oncogene, a hypothesis on the suppression of Fli1 by cardiotonic steroids as a potential anti-tumor therapeutic strategy is discussed as well. We propose a novel therapy of preeclampsia that is based on immunoneutralization of the marinobufagenin by monoclonal antibodies, which is capable of impairing marinobufagenin-Na/K-ATPase interactions.

Indexed as

AnimalsAntibodies, MonoclonalArteriesBufanolidesCarcinogenesisCardiac GlycosidesFemaleFibrosisHumansImmunotherapyPre-EclampsiaPregnancyProto-Oncogene MasProto-Oncogene Protein c-fli-1Signal TransductionSodium-Potassium-Exchanging ATPaseAntibodies, MonoclonalBufanolidesCardiac GlycosidesmarinobufageninMAS1 protein, humanProto-Oncogene MasProto-Oncogene Protein c-fli-1Sodium-Potassium-Exchanging ATPasecollagen-1Fli1marinobufageninNa/K-ATPasepreeclampsiaTFG-betavascular fibrosis

Identifiers

PMID33669287
PMCPMC7920043
OpenAlexW3129935539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.